磁共振成像上鉴别融合性肝纤维化与浸润性肝细胞癌
回顾性分析20例融合性肝纤维化与28例浸润性肝细胞癌患者的上腹部MRI,评估病灶影像特征并测量ADC值。病灶处肝包膜回缩、病灶处肝体积缩小及「结节环绕征」在融合性肝纤维化中更常见(均P<0.001);三项特征联合诊断融合性肝纤维化的敏感度达100.0%,任意两项或三项均阳性时特异度达100.0%。融合性肝纤维化的ADC值高于浸润性肝细胞癌(P<0.001)。
要点
- 病灶处肝体积缩小、动脉期无或轻度强化、延迟期较背景肝实质高强化三项联合诊断融合性肝纤维化敏感度100.0%、特异度100.0%。
- 融合性肝纤维化ADC值高于浸润性肝细胞癌(P<0.001),可辅助鉴别。
- 「结节环绕征」在融合性肝纤维化中更常见(P<0.001),为重要鉴别征象。
核心结论
- 病灶处肝体积缩小、动脉期无或轻度强化、延迟期较背景肝实质高强化三项特征联合可作为诊断融合性肝纤维化的可靠MR表现,有助于与浸润性肝细胞癌鉴别。
研究设计与样本
- 回顾性分析20例融合性肝纤维化患者和28例浸润性肝细胞癌患者的上腹部MRI资料,分析病灶影像特征并测量病灶ADC值。
关键影像表现/征象
- 病灶处肝包膜回缩、病灶处肝体积缩小及「结节环绕征」在融合性肝纤维化中较浸润性肝细胞癌更常见(均P<0.001)。
- 融合性肝纤维化的ADC值高于浸润性肝细胞癌(P<0.001)。
诊断标准与关键数值
- 病灶处肝体积缩小的诊断准确率为83.3%。
- 动脉期无或轻度强化的诊断准确率为85.4%。
- 延迟期较背景肝实质高强化的诊断准确率为97.9%。
- 病灶表现为病灶处肝体积缩小或动脉期无或轻度强化或延迟期较背景肝实质高强化时,诊断融合性肝纤维化的敏感度为100.0%。
- 病灶任意两项阳性或三项均阳性时,诊断融合性肝纤维化的特异度为100.0%。
临床应用与阅片要点
- 阅片时需关注病灶处肝包膜回缩、病灶处肝体积缩小及「结节环绕征」,上述征象支持融合性肝纤维化。
- 结合动脉期无或轻度强化、延迟期较背景肝实质高强化及ADC值升高,有助于与浸润性肝细胞癌鉴别。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: To identify reliable magnetic resonance imaging (MRI) features that can differentiate confluent fibrosis (CF) from infiltrative hepatocellular carcinoma (HCC).
METHODS: A retrospective analysis was conducted on Twenty CF patients and 28 infiltrative HCC patients who underwent upper abdomen MRI scans. The imaging features of lesions were analyzed, and the apparent diffusion coefficient (ADC) of lesions were measured. Accuracy, sensitivity and specificity for the diagnosis of CF were calculated for each category individually and combined.
RESULTS: Compared to infiltrative HCC, hepatic capsular retraction at the site of lesion, hepatic volume loss at the site of lesion and "nodular surround sign" were more common in patients with CF (all P < 0.001). Hepatic volume loss at the site of lesion, no or mild enhancement in arterial phase, and hyper-enhancing in delayed phase to the background parenchyma showed superior diagnostic accuracy (83.3%, 85.4%, 97.9%, respectively). When the lesion exhibited hepatic volume loss at the site of lesion or no or mild enhancement in arterial phase or hyper-enhancing in delayed phase, a sensitivity of 100.0% for the diagnosis of CF was achieved. When the lesion was positive for any two of three categories, or positive for all three categories, a specificity of 100.0% was achieved. The ADC values of CF were higher than those of infiltrative HCC (P < 0.001).
CONCLUSION: The combination of the hepatic volume loss at the site of lesion, no or mild enhancement in arterial phase, and hyper-enhancing in delayed phase to the background parenchyma can be considered reliable MR features for the diagnosis of CF, as they allow differentiation from infiltrative HCC.
引用
- Liu JJ, Duan MJ, Huang MY, et al. Differentiation of confluent hepatic fibrosis and infiltrative hepatocellular carcinoma on MR imaging. Abdom Radiol (NY). 2024. PMID: 38551668. doi:10.1007/s00261-024-04264-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。